Personality disorders

Drugs of the Future

Volumn 32, Issue 8, 2007, Pages 713-721

  McIntyre, J A ^a   Moral, Ma Àngels ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLONIDINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GUANFACINE; LAMOTRIGINE; MOOD STABILIZER; NALOXONE; NALTREXONE; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PHYSOSTIGMINE; PLACEBO; QUETIAPINE; RISPERIDONE; TOPIRAMATE; VALPROATE SEMISODIUM; ZIPRASIDONE;

AGGRESSION; AGITATION; ANGER; BEHAVIOR THERAPY; BIPOLAR DISORDER; BORDERLINE STATE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE CLASSIFICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; HUMAN; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; MOOD DISORDER; PERSONALITY DISORDER; PREVALENCE; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REVIEW; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; SEDATION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 35648951022     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.08.1125026     Document Type: Review

References (56)

1. Personality disorders. In: American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth edition, Text Revision. American Psychiatric Association Press, Washington, D.C., 2000, 685-729.
2. Lieb, K., Zanarini, M.C., Schmahl, C., Linehan, M.M., Bohus, M. Borderline personality disorder. Lancet 2004, 364(9432): 453-61.
3. Paris, J. Borderline personality disorder. CMAJ 2005, 172(12): 1579-83.
4. Bender, D.S., Dolan, R.T., Skodol, A.E. et al. Treatment utilization by patients with personality disorders. Am J Psychiatry 2001, 158(2): 295-302.
5. Binks, C.A., Fenton, M., McCarthy, L., Lee, T., Adams, C.E., Duggan, C. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev 2006, (1): CD005653.
6. Nose, M., Cipriani, A., Biancosino, B., Grassi, L., Barbui, C. Efficacy of pharmacotherapy against core traits of borderline personality disorder: Meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 2006, 21(6): 345-53.
7. Rinne, T., van den, Brink W., Wouters, L., van Dyck, R., SSRI treatment of borderline personality disorder: A randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 2002, 159(12): 2048-54.
8. Simpson, E.B., Yen, S., Costello, E., Rosen, K., Begin, A., Pistorello, J., Pearlstein, T. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry 2004, 65(3): 379-85.
9. DBT and escitalopram in borderline personality disorder (NCT00255554). ClinicalTrials.gov Web site, July 31, 2007.
10. Practice guideline for the treatment of patients with borderline personality disorder. American Psychiatric Association. Am J Psychiatry 2001, 158(10, Suppl.): 1-52.
11. Zanarini, M.C., Frankenburg, F.R. Olanzapine treatment of female borderline personality disorder patients: A double-blind, placebo-controlled pilot study. J Clin Psychiatry 2001, 62(11): 849-54.
12. Bogenschutz, M.P., Nurnberg, G.H. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004, 65(1): 104-9.
13. Zanarini, M.C., Frankenburg, F.R., Parachini, E.A. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 2004, 65(7): 903-7.
14. Soler, J., Pascual, J.C., Campins, J., Barrachina, J., Puigdemont, D., Alvarez, E., Perez, V. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry 2005, 162(6): 1221-4.
15. Schulz, S.C., Zanarini, M.C., Detke, H.C. et al. Olanzapine for the treatment of borderline personality disorder: A flexible-dose 12-week randomized double-blind placebo-controlled study. Eur Psychiatry [15th Eur Congr Psychiatry (March 17-21, Madrid) 2007] 2007, 22 (Suppl. 1): S172.
16. Zanarini, M.C., Schulz, S.C., Detke, H.C. et al. A dose comparison of olanzapine for the treatment of borderline personality disorder: A 12 week randomized double-blind placebo-controlled study. Eur Psychiatry [15th Eur Congr Psychiatry (March 17-21, Madrid) 2007] 2007, 22 (Suppl. 1): S172-3.
17. Pascual, J.C., Madre, M., Soler, J., Barrachina, J., Campins, M.J., Alvarez, E., Perez, V. Injectable atypical antipsychotics for agitation in borderline personality disorder. Pharmacopsychiatry 2006, 39(3): 117-8.
18. Damsa, C., Adam, E., De Gregorio, F., Cailhol, L., Lejeune, J., Lazignac, C., Allen, M.H. Intramuscular olanzapine in patients with borderline personality disorder: An observational study in an emergency room. Gen Hosp Psychiatry 2007, 29(1): 51-3.
19. PET imaging and olanzapine treatment in borderline personality disorder (NCT00275301). ClinicalTrials.gov Web site, July 31, 2007.
20. Villeneuve, E., Lemelin, S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: Impulsivity as main target. J Clin Psychiatry 2005, 66(10): 1298-303.
21. Bellino, S., Paradiso, E., Bogetto, F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study. J Clin Psychiatry 2006, 67(7): 1042-6.
22. Perrella, C., Carrus, D., Costa, E., Schifano, F. Quetiapine for the treatment of borderline personality disorder; an openlabel study. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31(1): 158-63.
23. Ortigosa, J.C., Sotomayor, E., Majadas, S., Garcia-Portilla, P., Bobes, J. The TREBOL study: Quetiapine in the borderline personality disorder: Patient's attitude and compliance. Eur Psychiatry [15th Eur Congr Psychiatry (March 17-21, Madrid) 2007] 2007, 22 (Suppl. 1): S175.
24. Verkes borderline study: The effect of quetiapine on borderline personality disordered patients (NCT00254748). ClinicalTrials.gov Web site, July 31, 2007.
25. Quetiapine treatment for symptoms associated with borderline personality disorder (NCT00122070). ClinicalTrials.gov Web site, July 31, 2007.
26. Rocca, P., Marchiaro, L., Cocuzza, E., Bogetto, F. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 2002, 63(3): 241-4.
27. Nickel, M.K., Muehlbacher, M., Nickel, C. et al. Aripiprazole in the treatment of patients with borderline personality disorder: A double-blind, placebo-controlled study. Am J Psychiatry 2006, 163(5): 833-8.
28. Nickel, M.K., Loew, T.H., Gil, F.P. Aripiprazole in treatment of borderline patients, part II: An 18-month follow-up. Psychopharmacology (Berl) 2007, 191(4): 1023-6.
29. Nickel, M.K., Nickel, C., Mitterlehner, F.O. et al. Topiramate treatment of aggression in female borderline personality disorder patients: A double-blind, placebo-controlled study. J Clin Psychiatry 2004, 65(11): 1515-9.
30. Loew, T.H., Nickel, M.K., Muehlbacher, M. et al. Topiramate treatment for women with borderline personality disorder: A double-blind, placebo-controlled study. J Clin Psychopharmacol 2006, 26(1): 61-6.
31. Topiramate for treatment of patients with borderline personality disorder and alcohol dependence (NCT00463775). ClinicalTrials.gov Web site, July 31, 2007.
32. Tritt, K., Nickel, C., Lahmann, C., Leiberich, P.K., Rother, W.K., Loew, T.H., Nickel, M.K. Lamotrigine treatment of aggression in female borderline-patients: A randomized, double-blind, placebo-controlled study. J Psychopharmacol 2005, 19(3): 287-91.
33. Weinstein, W., Jamison, K.L. Lamotrigine for affective instability in BPD. 158th Annu Meet Am Psychiatr Assoc (May 21-26, Atlanta) 2005, Abst NR547.
34. Bellino, S., Paradiso, E., Bogetto, F. Oxcarbazepine in the treatment of borderline personality disorder: A pilot study. J Clin Psychiatry 2005, 66(9): 1111-5.
35. Hollander, E., Allen, A., Lopez, R.P. et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001, 62(3): 199-203.
36. Simeon, D., Baker, B., Chaplin, W., Braun, A., Hollander, E. An open-label trial of divalproex extended-release in the treatment of borderline personality disorder. CNS Spectr2007, 12(6): 439-43.
37. Hollander, E., Tracy, K.A., Swann, A.C. et al. Divalproex in the treatment of impulsive aggression: Efficacy in cluster B personality disorders. Neuropsychopharmacology 2003, 28(6): 1186-97.
38. Bohus, M.J., Landwehrmeyer, G.B., Stiglmayr, C.E., Limberger, M.F., Bohme, R., Schmahl, C.G. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: An open-label trial. J Clin Psychiatry 1999, 60(9): 598-603.
39. Philipsen, A., Schmahl, C., Lieb, K. Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry 2004, 37(5): 196-9.
40. Naltrexone in borderline personality disorder (NCT00124839). ClinicalTrials.gov Web site, July 31, 2007.
41. Guanfacine to treat borderline personality disorder (NCT00358969). ClinicalTrials.gov Web site, July 31, 2007.
42. Philipsen, A., Richter, H., Schmahl, C., Peters, J., Rusch, N., Bohus, M., Lieb, K. Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. J Clin Psychiatry 2004, 65(10): 1414-9.
43. Kirrane, R.M., Mitropoulou, V., Nunn, M., Silverman, J., Siever, L.J. Physostigmine and cognition in schizotypal personality disorder. Schizophr Res 2001, 48(1): 1-5.
44. Keshavan, M., Shad, M., Soloff, P., Schooler, N. Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder. Schizophr Res 2004, 71(1): 97-101.
45. Koenigsberg, H.W., Reynolds, D., Goodman, M. et al. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry 2003, 64(6): 628-34.
46. McClure, M.M., Barch, D.M., Romero, M.J., Minzenberg, M.J., Triebwasser, J., Harvey, P.D., Siever, L.J. The effects of guanfacine on context processing abnormalities in schizotypal personality disorder. Biol Psychiatry 2007, 61(10): 1157-60.
47. Guanfacine for improving cognitive symptoms in people with schizotypal personality disorder (NCT00353379). ClinicalTrials.gov Web site, July 31, 2007.
48. Peris, L., Szerman, N. Risperidone in the treatment of paranoid personality disorder; Three case reports. Eur Psychiatry [14th Assoc Eur Psychiatr Congr (March 4-8, Nice) 2006] 2006, 21 (Suppl. 1):S246.
49. Hirose, S. Effective treatment of aggression and impulsivity in antisocial personality disorder with risperidone. Psychiatry Clin Neurosci 2001, 55(2): 161-2.
50. Greve, K.W., Adams, D. Treatment of features of obsessive-compulsive personality disorder using carbamazepine. Psychiatry Clin Neurosci 2002, 56(2): 207-8.
51. Zullino, D.F., Quinche, P., Hafliger, T., Stigler, M. Olanzapine improves social dysfunction in cluster B personality disorder. Hum Psychopharmacol 2002, 17(5): 247-51.
52. Kavoussi, R.J., Coccaro, E.F. Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J Clin Psychiatry 1998, 59(12): 676-80.
53. Eskandari, M.R., Karami, S. Efficacy of olanzapine in antisocial opioid addicts. 158th Annu Meet Am Psychiatr Assoc (May 21-26, Atlanta) 2005, Abst NR895.
54. Mauri, M.C., Fiorentini, A., Volonteri, L.S. et al. Quetiapine in acute psychosis and personality disorders during hospitalization: Assessment of a therapeutic range. Eur Neuropsychopharmacol 2004, 14(Suppl. 3): Abst P.2.116.
55. Preston, G.A., Marchant, B.K., Reimherr, F.W., Strong, R.E., Hedges, D.W. Borderline personality disorder in patients with bipolar disorder and response to lamotrigine. J Affect Disord 2004, 79(1-3): 297-303.
56. Frankenburg, F.R., Zanarini, M.C. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: A double-blind placebo-controlled pilot study. J Clin Psychiatry 2002, 63(5): 442-6.